ATS 2019 Virtual Final Program

BASIC • TRANSLATIONAL MINI SYMPOSIUM D16 EVERY CELL YOU BREAK: HOW CELLULAR PHENOTYPES CONTRIBUTE TO PAH 9:15 a.m. - 11:15 a.m. KBHCCD Ballroom D One (Level 3) Chairing: G. Kwapiszewska, PhD, Graz, Austria W.M. Oldham, MD, PhD, Boston, MA S. Graf, PhD, Cambridge, United Kingdom Oral Presentations 9:15 Lung Single-Cell Transcriptomics of Two Animal Models of Pulmonary Arterial Hypertension Reveals Vulnerable Cell Types and Pathways/ J. Hong, D. Arneson, I.S. Ahn, S. Umar, G. Diamente, M. Bhetraratana, C. Cunningham, M. Eghbali, X. Yang, Los Angeles, CA, p.A5867 9:30 Pulmonary Artery Endothelial Cell Phenotype Switch Impairs Angiogenesis in the Lungs in Persistent Pulmonary Hypertension of the Newborn/ G.G. Konduri, U. Rana, B. Entringer, E. Callan, R.-J. Teng, T. Michalkiewicz, Wauwatosa, WI, p.A5868 9:45 Primitive CD117+ Endothelial Cells Are a Putative Source of Mesenchymal Cells in Pulmonary Artery Hypertension/ A.R. Bhagwani, D. Farkas, M. Clauss, M. Yoder, R.J. Freishtat, L. Farkas, Richmond, VA, p.A5869 10:00 Pulmonary Hypertension and Metabolic Disease in Rats with Human Mutation in Fe-S Cluster Scaffold Protein NFU1/ O. Rafikova, M. Niihori, C.A. Eccles, M. Vasilyev, R. Rafikov, Tucson, AZ, p.A5870 10:15 Pathogenetic Role of Fatty Acid Oxidation in Human Lungs Affected by Pulmonary Arterial Hypertension/ M.H. Lee, J. Harral, D. Hernandez-Saavedra, L. Sanders, A. Gandjeva, B.B. Graham, R.M. Tuder, Aurora, CO, p.A5871 10:30 Metabolomics in Pulmonary Hypertension/ S.Y. Farha, S.A.A. Comhair, S. Kalhan, R. Zhang, B. Willard, M. Park, J.K. Sharp, K.B. Highland, W.H.W. Tang, S.C. Erzurum, Cleveland, OH, p.A5872 10:45 Paclitaxel, a FoxO1 Activator Reverses IL-6 Mediated Perinatal Metabolic Programming of Lung Micro-Vessels and the Risk of Pulmonary Arterial Hypertension/ V. Jentgen, K. Dinger, C. Vohlen, S. Dabral, J. Will, S. van Koningsbruggen-Rietschel, M. Odenthal, S.S. Pullamsetti, J. Dötsch, M.A. Alejandre Alcazar, Cologne, Germany, p.A5873 11:00 Antioxidant Conjugated Peptide Attenuated Metabolic Reprogramming in Pulmonary Hypertension/ M. Valuparampil Varghese, M. Niihori, S. Kurdyukov, C.A. Eccles, O. Rafikova, R. Rafikov, Tucson, AZ, p.A5874 BASIC • TRANSLATIONAL MINI SYMPOSIUM D17 TOWARDS THE NEXT IPF THERAPIES 9:15 a.m. - 11:15 a.m. KBHCCD Room C147/C148/C154 (Level 1) Chairing: M.R. Horton, MD, Baltimore, MD M. Peters-Golden, MD, Ann Arbor, MI C. Feghali-Bostwick, PhD, Charleston, SC Oral Presentations 9:15 Dual a V ß 6 / a V ß 1 Inhibitor PLN-74809 Reduces Fibrogenesis in Ex Vivo and In Vivo Models of IPF/ M. Decaris, J. Schaub, C. Chen, J. Cha, G. Lee, M. Rexhepaj, V. Rao, P. Kotak, L. Hooi, J. Wu, S. Martin, T. Chen, M. Munoz, T. Hom, K. Leftheris, D. Morgans, S. Turner, P. Andre, South San Francisco, CA, p.A5875 9:30 Engineered Lymphocytes Expressing Mutant Form of TGFß Block TGFß Pathway on Lung Fibroblasts/ J.C. Caraballo, N. Frankle, T. Tsukui, A.P. Hinck, W. Lim, D. Sheppard, San Francisco, CA, p.A5876 9:45 Cell Specific Targeting of the Rho-Kinase-MRTF Pathway Using Nanotechnology in a Mouse Model of Lung Fibrosis/ R.S. Knipe, C.K. Probst, M. Nurunnabi, J.J. Spinney, E. Abe, A. Franklin, T. Nguyen, B.D. Medoff, J.R. McCarthy, Boston, MA, p.A5877 10:00 A High-Throughput Small Molecule Screen for YAP Inhibitors Identifies Statins as Inhibitors of Fibroblast Activation and Pulmonary Fibrosis/ D.M. Santos, L. Pantano, G. Pronzati, P. Grasberger, C.K. Probst, K.E. Black, J.J. Spinney, R. Nichols, Y. Lin, D. Wyatt, A.M. Tager, B.D. Medoff, Boston, MA, p.A5878 10:15 Inhibition of BRD4 Down-Regulates Nox4 Expression by Blocking P300 Association with the Nox4 Promoter and Improves Resolution of Lung Fibrosis in a Bleomycin Model/ Y. Sanders, X. Lyv, L. Bai, Z. Xiang, Q. Zhou, S. Samuel, V.J. Thannickal, Birmingham, AL, p.A5879 10:30 ER Stress-Induced Stem Cell Failure and Lung Fibrosis Are Reversed by TUDCA/ B. Zhou, Y. Liu, H. Wang, P. Flodby, A. Lee, Z. Borok, Los Angeles, CA, p.A5880 10:45 Kruppel-Like Factor 4 (KLF4): A Brake on Fibroblast Activation and A Target for Pharmacologic Induction in Pulmonary Fibrosis/ L.R.K. Penke, H. Ouchi, C. Draijer, B. Hu, J. Speth, S.H. Phan, M. Peters-Golden, Ann Arbor, MI, p.A5881 11:00 BMS-986278, an LPA 1 Receptor Antagonist for Idiopathic Pulmonary Fibrosis: Preclinical Assessments of Potential Hepatobiliary Toxicity/ M.W. Gill, S. Lakshmi, P.T.W. Cheng, B.J. Murphy, K. Chadwick, L. Lehman-McKeeman, M. Graziano, Princeton, NJ, p.A5882 ATS 2019 • Dallas, TX 320 WEDNESDAY • MAY 22